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Abstract
Background: Cancer during pregnancy is relatively rare but may lead to maternal mortality. We aimed to assess
the incidence of cancer related maternal mortality and the neonatal outcome in these patients. Also, doctor- and
patient-related delay in cancer diagnosis and therapy among patients with cancer related maternal mortality
is assessed.
Methods: Maternal mortality was defined as death during pregnancy or within 1 year after delivery. Data of
the Dutch Maternal Mortality Committee was used to calculate the cancer related maternal mortality rate and
to assess neonatal outcome in the Netherlands. Delay was scored by ten medical specialist based on case
descriptions.
Results: Cancer related maternal mortality rate was 1.23 per 100,000 live births. Delay in either diagnosis or
treatment occurred in 65%. Delay in diagnosis was more frequent then delay in treatment, and was mainly
caused by health care providers. Only 77% of pregnancies were ongoing, and 65% ended preterm of which
85% was induced.
Conclusions: Avoiding delay in diagnosis and therapy in case of pregnancy related cancer could potentially
improve maternal and neonatal outcome. It is therefore essential to increase awareness among health care
providers about the occurrence and recurrence of cancer in pregnancy and the possibilities of diagnostic and
therapeutic interventions in these women.
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Background
In western countries, maternal mortality, defined as
death occurring during pregnancy or within the first
year after delivery, is a relatively small but still serious
problem. Most women die of pregnancy related prob-
lems, but approximately 25% of the maternal deaths are
non- pregnancy related. Pregnancies complicated by
cancer are a potential threat for both maternal and fetal
wellbeing. Incidence of cancer during pregnancy has
been estimated to be one in 1000 pregnancies, but due
to increasing maternal age and the increasing incidence
of risk factors for cancer, e.g. obesity, this incidence is
rising [1, 2]. Schutte et al. reported no cancer related
maternal deaths between 1983 and 1992 and three
between 1993 and 2005 [3].
If standard therapy is started without delay, prognosis
of pregnant patients is comparable to non-pregnant pa-
tients when corrected for maternal age and stage. Cancer
related symptoms can mimic those of physiological preg-
nancy changes [4]. They may be interpreted by both
patient and health care providers as pregnancy related,
delaying an accurate diagnosis [5, 6]. This delay can lead
to a more advanced stage of disease, causing a higher
mortality rate [7].
In the management of pregnant patients with cancer,
the unborn child is an important second patient that
needs to be taken care of. Treatment regimens must be
carefully evaluated in order to ensure fetal safety. Recent
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studies have shown that several cancer treatments seem
to be feasible during pregnancy without increasing the
change of congenital malformations [8, 9]. Chemo-
and radiotherapy during pregnancy does not seem to
affect the neuropsychological development up to 3
years. Unfortunately, substandard and/or delayed treat-
ment and iatrogenic preterm birth is still a major prob-
lem in this specific patient group [10]. In fact, preterm
delivery is a high risk factor for developmental prob-
lems later in life [8].
In advanced stages of disease, treatment is often more ex-
tensive and maternal condition deteriorated. Minimizing
delay in diagnosis will not prevent all maternal deaths, but
the outcome for both mother and neonate is likely to be
improved. However, literature on current cancer related
maternal mortality is scarce. Therefore, in the present study
the incidence of cancer related maternal mortality in the
Netherlands will be calculated and the occurrence of
doctor- and patient-related delay in diagnosis and therapy
will be evaluated. Finally, the neonatal outcome of the
children of the mothers that died of cancer during
pregnancy will be analysed.
Methods
This study is a nationwide observational cohort study
using the non-public database of the Dutch Maternal
Mortality Committee (MMC) after written permission of
the board of the committee. The methods of the MMC
and definitions of maternal mortality used have been
described previously [3]. Briefly, the MMC discusses re-
ported cases, collects missing data and evaluates the
avoidability of maternal mortality. Maternal mortality is
defined as death occurring during pregnancy or within
the first year after delivery. Their database is cross-
checked with the Central Bureau of Statistics of the
Netherlands (CBS). Missing cases are anonymously
added to the database.
Selection criteria and data collection
Patients registered between 2001 and 2012 by the MMC
who died during pregnancy or within 1 year postpartum
were screened. We selected the patients that died
because of (recurrent) cancer. Patients with cancer re-
lated symptoms during pregnancy but diagnosed after
delivery were included. If patients died from cancer but
only showed symptoms after delivery, they were not eli-
gible. Missing data in the reports of the MMC were
completed by review of the medical files. Ten medical
specialists from different disciplines, including medical
oncologists, gynaecological oncologists and obstetricians,
were provided detailed case descriptions, with informa-
tion on diagnosis and therapy. They scored anonymously
whether delay had occurred and whether this was doc-
tor- and/or patient-related delay. Delay was defined as
an extension of the period between symptoms/presenta-
tion and diagnosis, and diagnosis and treatment, com-
pared to optimal care based on expert opinions. For the
patients with recurrent disease during pregnancy, delay
was assessed from the moment of the new onset of
symptoms caused by recurrent disease. Delay due to
other primary health care providers like midwifes were
considered to be doctor-related delay.
Statistical analysis
Because of the observational nature of this study, statis-
tical analysis was restricted to descriptive statistics and
the evaluation of inter-observer agreement with a kappa
score. Because our data was scored by a fixed number of
observers using a numeric scorings system the Fleiss
kappa score was used.
Results
Incidence and maternal mortality rate
Between 2001 and 2012, 32 cancer related maternal
deaths were reported to the MMC. Four of these cases
were excluded: two patients were treated with chemo-
therapeutic agents for other indications than malignant
disease, one patient had a benign brain tumour and one
patient became symptomatic after delivery. Two
additional anonymous cases were reported by the CBS,
which were included but could only be used to calculate
the incidence of cancer related maternal mortality. The
26 remaining cases were available for analysis of delay.
With an average number of 188,604 live births per year
(range 202,603 in 2001 to 175,959 in 2012) in the
Netherlands, the Dutch cancer related MMR between
2001 and 2012 was 1.23 per 100,000 live births [11].
Patient characteristics
Brain tumours, gastro-intestinal tumours and melano-
mas were the most common types of cancer causing ma-
ternal mortality. Patient characteristics are shown in
Table 1. The median maternal age at diagnosis was
34 years (range 27–45 years). Of the 26 patients, 73%
was diagnosed during pregnancy; one patient (4%) was
diagnosed in the first trimester, ten patients (39%) in the
second trimester and eight patients (31%) in the third
trimester. Seven patients (27%) were diagnosed after de-
livery, but experienced cancer related symptoms during
pregnancy. Median survival after diagnosis was 101 days
with a range of 3–352 days. Stage IV disease was present
at diagnosis in 90% of the patients; the other 10% had
stage III disease. Four patients had recurrent disease
during pregnancy and were diagnosed with advanced
stage disease at recurrence while pregnant; one melan-
oma and three astrocytomas.
Standard curative therapy was applied in nine cases.
Four patients received adjusted treatment because of
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Table 1 Patient characteristics
Patient Tumour Parity GA a.d.
(wks)
Stage/grade a.d.
(TNM/FIGO)
Survival after
diagnosis (days)
One-year
survival in
general (%)
Patient/
doctor delay
in diagnosis
Patient/doctor
delay in treatment
Obstetrical outcome
1 Adrenal
carcinoma
G5P3 Pp IV 133 Unknown Inconclusive No GA 36 weeks; induction for
suspicion of HELLP syndrome,
but were metastasis.
2 Astrocytoma G1P0 Pp II 92 84 Yes, both Yes, doctor GA 38 weeks; induction for
HELLP syndrome
3 Breast cancer G2P1 Pp IV 9 72 Yes, doctor No GA 37 weeks; SVD
4 Breast cancer G9P6 12 IV 310 72 NA No GA 32 weeks; emergency CS
when patient was found in
coma.
5 Breast cancer G3P2 Pp IV 126 72 Yes, patient Yes, patient GA 39 weeks; induction for
excessive skeletal pains
6 Cervical
carcinoma
G2P1 25 IV 352 44–54 No No GA 34 weeks; maternal
deterioration
7 Cholangio-
carcinoma
G3P0 28 IV 81 13 Yes, doctor No GA 28 weeks; CS for fetal
distress
8 Esophagus
carcinoma
G5P4 28 IV 78 20 No No GA 36 weeks; induction for
therapy planning
9 Esophagus
carcinoma
G1P0 17 Unknown 110 29 NA Yes, doctor IUFD at GA 22 weeks
10 Gastric
carcinoma
G3P1 23 IV 78 17 No No GA 29 weeks; CS for maternal
deterioration and breech
position
11 Gastric
carcinoma
G2P1 18 IV 171 17 Yes, doctor No GA 18 weeks; immature
delivery after surgery.
12 Glioblastoma
multiforme
G14P10 16 IV 87 38 No No IUFD at GA 27 weeks
13 Glioblastoma
multiforme
G2P1 28 IV 270 38 Yes, doctor Yes, patient GA 34 weeks; CS for twin and
maternal deterioration
14 Glioblastoma
multiforme
G4P3 16 IV 15 38 Yes, doctor No Died while pregnant
(GA 18 weeks)
15 Lung carcinoma G2P1 36 IV 149 22 Yes, both NA GA 36 weeks; induction for
therapy planning
16 Melanoma G1P0 26 IV 15 32 No NA Died while pregnant
(GA 29 weeks)
17 Melanoma G2P1 21 IIIC 154 82 No Yes, doctor Term; SVD
18 Melanoma G4P2 Pp IV 47 32 Yes, doctor No GA 40 weeks; SVD
19 Melanoma G1P0 16 IV 167 32 No Yes, patient GA 32 weeks; fetal distress
20 Non-Hodgkin
lymphoma
G3P2 Pp IVB 20 67 Yes, doctor No Term; SVD
21 Ovarian
carcinoma
G2P1 34 IIIB 176 77 Yes, patient No GA 35 weeks; induction for
therapy planning
22 Pancreatic
carcinoma
G1P0 24 IV 37 10 No No GA 28 weeks; SVD
23 Pilocytic
astrocytoma
G2P1 17 I 3 89 No No Died during pregnancy
(GA 17 weeks)
24 Rectum
carcinoma
G2P1 37 IV 134 46–70 Yes, doctor No GA 37 weeks; induction after
diagnosis.
25 Satellite tumour
CNS
G1P0 21 III 130 61 No Yes, doctor GA 34 weeks; CS for maternal
deterioration
26 Unknown
primary tumour
G1P0 Pp IV 82 – Yes, NA No GA 26 weeks; CS for HELLP.
Neonatal death after 4 days.
Pp postpartum, G gravidity, P parity, a.d. at diagnosis, NA not assessable, GA gestational age, HELLP hemolysis, elevated liver enzymes, and low platelet count, CS
caesarean section, SVD spontaneous vaginal delivery, IUFD intra-uterine fetal death, CNS central nervous system
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pregnancy or complications. In six cases, the patient de-
cided to postpone treatment until a higher gestational
age (GA). Four of these patients were still induced pre-
term. Palliative care was the only option for six patients.
For one patient, data on therapeutic decision-making
was not available.
Obstetrical outcome
Obstetrical outcome was available for all 26 patients
with detailed case information (Fig. 1). Five pregnancies
were complicated by intra-uterine fetal death: 1) at a GA
of 17 weeks, when mother died of an astrocytoma, 2) at
a GA of 18 weeks, when mother died of a glioblastoma
multiforme, 3) at a GA of 22 weeks after suboptimal in-
tubation during surgery, 4) at a GA of 27 weeks, when
mother was admitted with a status epilepticus due to
progressive glioblastoma multiforme, and 5) at a GA of
29 weeks, when the mother died suddenly at home due
to metastatic melanoma. One patient experienced an im-
mature delivery at a GA of 18 weeks after a bilateral
laparotomic oophorectomy.
Of the 20 ongoing pregnancies ending in a live birth,
one was a twin pregnancy resulting in 21 live new-
borns. However, one of the children died 4 days after
caesarean section at a GA of 26 weeks due to complica-
tions of extreme preterm delivery. Caesarean section was
performed because of presumed HELLP syndrome. After
delivery, the complaints progressed and stage IV cancer
of unknown origin with liver metastases was diagnosed.
Median GA at delivery of all 20 ongoing pregnancies
was 35 weeks (range 26–40 weeks). Thirteen (65%) of
these ended preterm, of which 11 deliveries (85%) were
vaginally induced (n = 3) or terminated by caesarean
section (n = 8). Reasons for iatrogenic preterm delivery
were maternal deterioration (n = 4), therapy planning
(n = 4) or obstetrical complications (n = 3).
Doctor-related and patient-related delay
Ten medical specialists dealing with pregnant cancer pa-
tients from six different medical centres independently
scored all 26 case descriptions on delay in diagnosis and
treatment. The score was considered conclusive if six or
more specialists shared the same opinion.
See Table 2 for an overview of the types of delay. In
65% of patients (n = 17) delay was found to be present,
50% (n = 13) or all patients were found to have delay in
diagnosis and 27% (n = 7) in starting therapy. Three pa-
tients were considered to have both types of delay.
Regarding the other nine cases, six showed no signs of
delay, two had not enough information available for ad-
equate evaluation and one score was inconclusive. Even
in patients with recurrent disease, delay in diagnosis oc-
curred in 50%. In one of these patients with recurrent
astrocytoma, delay was caused by doctors in a non-
academic centre where symptoms like increasing blood
pressure, headache and general seizure were interpreted
as eclampsia, for which delivery was induced. In the
other patients with delay in diagnosis with recurrent
melanoma, progressive back pain and pain on her
ribcage at a GA of 35 weeks, was treated with pain
medication until 2 weeks after delivery. Diagnostic inves-
tigations showed wide spread melanoma metastasis
including bones and lungs.
Inter-observer agreement on the presence of delay in
diagnosis was found to be substantial, with a Fleiss Kappa
Fig. 1 Obstetrical outcome for all 26 pregnancies
Table 2 Delay in diagnosis and treatment
Type of delay No. %
Overall delay 17 65
Delay in diagnosis 13 50
- Doctor-relateda 8 62
- Patient-relateda 2 15
- Doctor- and patient relateda 2 15
- Not assessablea 1 4
Delay in therapy 7 27
- Doctor-relateda 4 15
- Patient-relateda 3 12
aOf all patients with delay
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score of 0.71. The agreement for the delay in therapy was
less, with a score of 0.33, which is a fair agreement.
In the cases where delay in diagnosis was caused, the
origin was evaluated to assess whether the delay was
caused by the involved health care provider or by the
patient. In eight of 13 patients with delay in diagnosis,
doctor-related delay was considered to have influenced
the time between presentation of symptoms and
diagnosis. In two additional cases, both the health care
provider and the patient caused delay. For the ten pa-
tients with doctor-related delay, delay was caused by the
midwife (n = 5), general practitioner (n = 2) and by doc-
tors from a non-academic centres (n = 2) and in two
patients, multiple non-academic health care workers
caused delay. In nine cases, symptoms were described as
pregnancy related complaints, and in one patient, a
wrong diagnosis was made based on additional diagnos-
tic tests. In one patient, delay was caused by a long
period between referral to a hospital and actual diagnos-
tic evaluation. Patient-related delay in diagnosis was
present in only two cases, and in one case enough infor-
mation was not available to evaluate the cause of delay.
Doctor-related delay in therapy was found in four of
the seven cases. In the other three cases, patients refused
the advised treatment during pregnancy and wished to
delay until after delivery.
Discussion
This is, to our knowledge, the second study to evaluate
specific cancer related MMR and the first to report on
delay in either diagnosis or treatment and obstetrical
outcome in this specific population. The cancer related
MMR in the Netherlands between 2001 and 2012 was
1.23 per 100,000 live births, with the highest incidence
of cause related death due to brain tumours, gastro-
intestinal tumours and melanomas. Delay in diagnosis
was more frequent than delayed treatment, and was
mainly caused by health care providers. Of the 77% on-
going pregnancies, 65% delivered preterm, often after
induction of labour for oncological reasons. One neo-
natal death occurred.
The only other article published on cancer related ma-
ternal mortality, in 1990 by Sachs et al. [12], reported on
their population-based study in the USA between 1954
and 1985 and found a cancer related MMR of 1.44. They
defined maternal mortality as death during pregnancy or
within 90 days after delivery. Because this is different from
the current WHO definition used in our study, comparing
these results to this present study is not feasible [12].
The outcome for pregnant patients with cancer is not
different from non-pregnant patients when corrected for
stage and age at diagnosis [7]. Previous literature has
reported that patients with cancer during pregnancy
present with a more advanced stage of disease due to
delay in diagnosis [5, 6]. Since stage of disease at diagnosis
is strongly correlated to prognosis, this delay may contrib-
ute to a worse maternal outcome and should be avoided
where possible. For some tumours, the effect of delay on
the prognosis is less, since lower stage of disease still has a
poor prognosis. However, even in these cases, prognosis is
better when diagnosed in an earlier stage.
Delay in therapy until after delivery may postpone ad-
equate therapy for the mother, thereby contributing to a
worse maternal prognosis. If preterm induction of labour
is aimed for to start therapy postpartum, the prognosis
of the unborn child is influenced as well. A recent study
[8] showed that there was no difference between neuro-
psychological development between children exposed to
chemotherapy in utero and healthy controls. In fact, pre-
term birth had a bigger impact on neuropsychological
outcome in both groups with an increase of 2.6 IQ
points per week gestation at birth [8]. In our study
population, delay in diagnosis may have contributed to a
more advanced stage of disease requiring systemic ther-
apy in order to improve survival. In 27% of the cases,
therapy was delayed until spontaneous delivery or until
a certain GA was reached and pregnancy could be ter-
minated. Raising awareness on cancer in pregnancy and
the possibilities in diagnostic and therapeutic treatment
modalities among health care providers may help in re-
ducing the morbidity and mortality of these patients and
their children.
One of the main limitations of our study include that
reporting fatalities to the Dutch MMC is on a voluntary
basis. Even though the committee is well known among
gynaecologists, it is possible that a year after pregnancy,
the relation between death and pregnancy by other med-
ical professionals may be overlooked. Cross checking
with the CBS database revealed only two more cases,
but the actual number of cancer related (late) mortalities
might be higher than reported. Furthermore, there are
some difficulties in studying delay, as the extent of delay
for one tumour will not have the same consequences as
delay for another, more aggressive, tumour and if cura-
tive therapeutic options are not available, delay will not
change the fatal outcome. However, the various medical
specialists reached an overall agreement on the occur-
rence of delay, which makes our findings more reprodu-
cible. Our study population is small, because of the low
incidence of cancer related maternal mortality.
We cannot exclude that treatment in a multidisciplinary
team may influenced outcome. Practitioners with experi-
ence in oncologic treatment in pregnancy will probably
hesitate less to start treatment, but they are often
dependent on referral from first-line healthcare workers
and they cannot change the stage of cancer. This empha-
sizes that awareness in all practitioners is essential.
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Conclusions
In conclusion, cancer related maternal mortality is rare
but contributes to high neonatal morbidity and mortality
rates, mainly due to iatrogenic preterm delivery. Delay
in diagnosis and treatment occurs frequently in this
group and is mainly caused by health care providers.
This can only be resolved by increased awareness among
health-care professionals.
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